{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:26:58Z","timestamp":1758479218229},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,20]]},"DOI":"10.7759\/cureus.29377","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:09:03Z","timestamp":1663718943000},"source":"Crossref","is-referenced-by-count":1,"title":["A Therapy-Terminating Event: Programmed Death-1 Inhibitor-Induced Mucositis"],"prefix":"10.7759","author":[{"given":"Dawson","family":"Foster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Karam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri","family":"Nadella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Adekunle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merra","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Sokhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3033279","article-title":"Assessment of the evolution of cancer treatment therapies","volume":"3","author":"Arruebo M","year":"2011","unstructured":"Arruebo M, Vilaboa N, S\u00e1ez-Gutierrez B, Lambea J, Tres A, Valladares M, Gonz\u00e1lez-Fern\u00e1ndez A. Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2011, 3:3279-330. 10.3390\/cancers3033279","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker DM","year":"2015","unstructured":"Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015, 7:9-14. 10.4161\/19420862.2015.989042","journal-title":"MAbs"},{"key":"ref3","unstructured":"Milestones in Cancer Research and Discovery. (2020). Accessed. November 28, 2021: https:\/\/www.cancer.gov\/research\/progress\/250-years-milestones."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest JM","year":"2017","unstructured":"Yoest JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017, 6:73-82. 10.2147\/ITT.S126227","journal-title":"Immunotargets Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck L","year":"2017","unstructured":"Dyck L, Mills KH. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017, 47:765-79. 10.1002\/eji.201646875","journal-title":"Eur J Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.01.028","article-title":"Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm","volume":"56","author":"Rao M","year":"2017","unstructured":"Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M. Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis. 2017, 56:221-8. 10.1016\/j.ijid.2017.01.028","journal-title":"Int J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.24353","article-title":"Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1\/pd-l1 against oral cancer? A systematic review","volume":"26","author":"Pe\u00f1a-Cardelles JF","year":"2021","unstructured":"Pe\u00f1a-Cardelles JF, Salgado-Peralvo AO, Garrido-Mart\u00ednez P, Cebri\u00e1n-Carretero JL, Pozo-Kreilinger JJ, Moro-Rodr\u00edguez JE. Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1\/pd-l1 against oral cancer? A systematic review. Med Oral Patol Oral Cir Bucal. 2021, 26:e494-501. 10.4317\/medoral.24353","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok JD","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G, et al.. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010, 11:155-64. 10.1016\/S1470-2045(09)70334-1","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian SL","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al.. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012, 366:2443-54. 10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber JS","year":"2008","unstructured":"Weber JS, O'Day S, Urba W, et al.. Phase I\/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008, 26:5950-6. 10.1200\/JCO.2008.16.1927","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer JR","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, et al.. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010, 28:3167-75. 10.1200\/JCO.2009.26.7609","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid O","year":"2013","unstructured":"Hamid O, Robert C, Daud A, et al.. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013, 369:134-44. 10.1056\/NEJMoa1305133","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik A","year":"2015","unstructured":"Patnaik A, Kang SP, Rasco D, et al.. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015, 21:4286-93. 10.1158\/1078-0432.CCR-14-2607","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert C","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, et al.. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014, 384:1109-17. 10.1016\/S0140-6736(14)60958-2","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0204-3","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors","volume":"30","author":"Day D","year":"2016","unstructured":"Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs. 2016, 30:571-84. 10.1007\/s40259-016-0204-3","journal-title":"BioDrugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.02.011","article-title":"Toxicity patterns with immunomodulating antibodies and their combinations","volume":"42","author":"Haanen JB","year":"2015","unstructured":"Haanen JB, Thienen Hv, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015, 42:423-8. 10.1053\/j.seminoncol.2015.02.011","journal-title":"Semin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01715-7","article-title":"Oral mucositis: the hidden side of cancer therapy","volume":"39","author":"Pulito C","year":"2020","unstructured":"Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020, 39:210. 10.1186\/s13046-020-01715-7","journal-title":"J Exp Clin Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20162","article-title":"Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients","volume":"100","author":"Sonis ST","year":"2004","unstructured":"Sonis ST, Elting LS, Keefe D, et al.. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004, 100:1995-2025. 10.1002\/cncr.20162","journal-title":"Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-8140(97)00174-6","article-title":"Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial","volume":"47","author":"Leborgne JH","year":"1998","unstructured":"Leborgne JH, Leborgne F, Zubizarreta E, Ortega B, Mezzera J. Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol. 1998, 47:145-8. 10.1016\/s0167-8140(97)00174-6","journal-title":"Radiother Oncol"},{"key":"ref20","article-title":"","year":"1979","unstructured":"WHO Handbook For Reporting Results of Cancer Treatment. World Health Organization, Geneva, Switzerland; 1979. https.\/\/apps.who.int\/iris\/handle\/10665\/37200."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.761","article-title":"Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice","volume":"5","author":"Peterson DE","year":"2016","unstructured":"Peterson DE, O'Shaughnessy JA, Rugo HS, et al.. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016, 5:1897-907. 10.1002\/cam4.761","journal-title":"Cancer Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2013.02.022","article-title":"Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management","volume":"116","author":"Nicolatou-Galitis O","year":"2013","unstructured":"Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, Papadopoulou E, Sonis S. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013, 116:e110-6. 10.1016\/j.oooo.2013.02.022","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2017.10.01","article-title":"Chemotherapy induced oral mucositis: prevention is possible","volume":"7","author":"Cidon EU","year":"2018","unstructured":"Cidon EU. Chemotherapy induced oral mucositis: prevention is possible. Chin Clin Oncol. 2018, 7:6. 10.21037\/cco.2017.10.01","journal-title":"Chin Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s005209900076","article-title":"Efficacy of treatment to relieve mucositis-induced discomfort","volume":"8","author":"Turhal NS","year":"2000","unstructured":"Turhal NS, Erdal S, Karacay S. Efficacy of treatment to relieve mucositis-induced discomfort. Support Care Cancer. 2000, 8:55-8. 10.1007\/s005209900076","journal-title":"Support Care Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1191\/1078155205jp166oa","article-title":"Survey of topical oral solutions for the treatment of chemo-induced oral mucositis","volume":"11","author":"Chan A","year":"2005","unstructured":"Chan A, Ignoffo RJ. Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. J Oncol Pharm Pract. 2005, 11:139-43. 10.1191\/1078155205jp166oa","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/107626-a-therapy-terminating-event-programmed-death-1-inhibitor-induced-mucositis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:53Z","timestamp":1707507593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/107626-a-therapy-terminating-event-programmed-death-1-inhibitor-induced-mucositis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.29377","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}